STMN2 and neuroblastoma: Having validated the pan-cancer STMN2.SIG’s utility in predicting immunotherapy response, we next investigated its broader applicability in pediatric cancer prognosis, which is our research focus for pediatric surgeons, as frontline immunotherapy is not standard in NB.